NSCLC (squamous or non-squamous) is the most common type of lung cancer, which is the leading cause of cancer death in the United States. In the past several years, both targeted and immuno-therapies (IO) have been rapidly developed for NSCLC. Patients with typical NSCLC alterations (e.g., EGFR, ALK, ROS1, BRAF, MET, RET, NTRK) have effective FDA-approved therapy options, and several potential targets are currently being evaluated in clinical trials. IO monotherapies and combinations have also been incorporated into treatment algorithms due to rapid responses and long survival times. An unmet need remains for NSCLC patients with progression on IO and patients with currently untargeted alterations.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in NSCLC to help guide strategic and tactical commercial development decisions for market participants.